论文部分内容阅读
近几十年来,已建立了多种增强免疫原性的方法,如铝盐、蛋白体、免疫刺激复合物(ISCOM)、脂质体、与细菌产物或衍生物连接、与表面活性剂结合及细胞因子的应用。作者设计了一种以免疫增强性重组流感病毒体(IRIV)为佐剂的甲型肝炎灭活疫苗,在这种新疫苗中作者结合了几种不同的免疫刺激作用:磷脂囊泡的免疫增强作用,免疫系统对血凝素(HA)抗原决定簇的识别,HA对含有唾液酸的巨噬细胞和免疫活性细胞受体的结合力以及HA通过激发膜融合,介导抗原进入巨噬细胞胞质。这种新疫苗在甲型肝炎病毒(HAV)抗体阴性的志愿者中具有良好的免疫原性,且局部反应轻微.因此,IRIV为今后佐剂疫苗的设计提供了一种新方法。
In recent decades, a number of methods have been established to enhance immunogenicity, such as aluminum salts, proteosomes, immunostimulating complexes (ISCOMs), liposomes, conjugation to bacterial products or derivatives, conjugation to surfactants and Application of cytokines. The authors devised an inactivated hepatitis A vaccine adjuvanted with an immunologically-enhanced recombinant influenza virus (IRIV) in which the authors combined several different immunostimulatory effects: immune enhancement of phospholipid vesicles The recognition of the hemagglutinin (HA) epitope by the immune system, the binding of HA to the receptors of sialic acid-containing macrophages and immunocompetent cells, and the fusion of HA by an activating membrane mediate the entry of antigens into macrophage cells quality. This new vaccine has good immunogenicity in HAV antibody-negative volunteers and local reactions are mild, so IRIV provides a new method for the design of adjuvanted vaccines in the future.